Compare TRGP & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRGP | RMD |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7B | 34.0B |
| IPO Year | 2010 | 1996 |
| Metric | TRGP | RMD |
|---|---|---|
| Price | $283.15 | $221.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $257.29 | ★ $292.56 |
| AVG Volume (30 Days) | 926.4K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.00% | 1.13% |
| EPS Growth | ★ 47.91 | 9.67 |
| EPS | 5.75 | ★ 10.43 |
| Revenue | ★ $17,028,300,000.00 | $2,957,013,000.00 |
| Revenue This Year | $30.33 | $10.60 |
| Revenue Next Year | $6.55 | $7.41 |
| P/E Ratio | $49.22 | ★ $21.31 |
| Revenue Growth | 3.95 | ★ 13.44 |
| 52 Week Low | $144.14 | $180.27 |
| 52 Week High | $307.94 | $284.87 |
| Indicator | TRGP | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 48.69 |
| Support Level | $254.47 | $217.10 |
| Resistance Level | $291.04 | $233.94 |
| Average True Range (ATR) | 7.14 | 4.77 |
| MACD | -1.54 | -0.96 |
| Stochastic Oscillator | 10.04 | 42.20 |
Targa Resources Corp is a midstream firm that mainly operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset. It has two operating segments: Gathering and Processing, and, Logistics and Transportation (also referred to as the Downstream Business).
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.